2020 has been a banner year for the psychedelic therapy market and is a vertical that we have been highly focused on. So far this year, there has been a large increase in the number of companies that are focused on this burgeoning market and this is a trend that our readers should be aware of. Although there has been a significantly increased in interest in psychedelic businesses, investors must be selective and focus on companies that have a real business and are led by management team with a proven track record of success.
When it comes to the psychedelic therapy market, we are excited about the potential medical benefits that are associated with psilocybin, which has recently been granted its second Breakthrough Therapy Designation (BTD) for the treatment resistant depression by the FDA. We are favorable on how the industry is advancing through such significant recognition including Fast Track Designation and Orphan Drug Discovery. We have been highly focused on the psilocybin market and want to highlight a company that has been executing on this vertical.
Silos Wellness is a vertically integrated recreational psilocybin mushrooms company that is based in Oregon with operations in Jamaica. The psychedelics intellectual property holding company has an attractive operating structure that includes cultivation, Jamaica based psilocybin retreats, and product development.
In late 2019, Silo recorded a major milestone and unveiled the first-ever psilocybin nasal spray for controlled, metered micro-dosing. A primary benefit of the nasal spray is that it bypasses the stomach and goes directly to the bloodstream through the nasal mucus membranes and eventually to the liver for metabolizing. This helps control the gastrointestinal side effects that are associated with mushrooms and we find this to be a major differentiator for the business.
Another attractive aspect of Silo is related to the work it is doing with exploring opportunities for DMT/ayahuasca therapy and functional mushrooms. We are favorable on the number of avenues that Silo has for growth and believe that it is an opportunity to be aware of.
Led by a Management Team that has Been Ahead of the Curve
In 2017, Silo’s founder Mike Arnold made headlines when he left his law practice to cultivate 40,000 cannabis plants in Oregon. We are favorable on the expertise that he adds to the business and the vision that Mike has with high-growth markets. Shortly after realizing that the cannabis industry was becoming saturated, Mike started working with the inventor of the patent-pending Mystabis hemp and marijuana inhalers on the development of metered-dosing solutions of sub-psychedelic or psychedelic treatment.
Silo Wellness is led by a management team that has been successful in the field of cannabis delivery modalities and we find this to be of importance. The team has developed a magic mushroom nasal spray for controlled, metered-dosing consumer micro-dosing. Silo expects new users to be more excited about experimenting with micro-dosed products prior to committing to consuming a larger amount of psilocybin and we agree with this logic.
Before legislation passed in Denver, Silo was already following the Oregon initiative petition process and has been an early mover on the psychedelic market. After Denver passed its decriminalization ballot, we saw a substantial increase in the amount of interest in psychedelic companies and we are favorable on the Silo’s ability to be ahead of the curve.
After Silo finished formulating its product line in Jamaica, Missouri pharmacologist Parag Bhatt, who led the study, and Silo COO Scott Slay were the first people to test the product. The initial feedback from people who have tried the product has been positive and we are favorable on how the team were among the first to try the product.
Taking Pre-Order and Entertaining Licensing Proposals
After conducting a significant amount of research and testing of the product, Silo began to accept pre-orders and is now entertaining licensing proposals for research and for manufacturing the product ahead of new markets becoming legal. We are bullish on the amount of interest the product has generated so far and will monitor how the management team is able to capitalize on this.
We believe that Silo represents a differentiated growth opportunity and is a business that we are excited about. Silo has visible growth prospects and we will monitor how the management team is able to bring its nasal spray product to market.
Silo is working to execute on a multi-faceted growth strategy and is an opportunity to be aware of. If you are interested in learning more about the psychedelics intellectual property holding company, please send an email to firstname.lastname@example.org to be added to our distribution list.